spec sheet9 rows
MPT (N-methyl-N-propyltryptamine) is an obscure synthetic tryptamine carrying a methyl and a propyl group on the terminal amine, structurally analogous to the N,N-dialkyltryptamines explored in psychedelic research. Like related tryptamines, it is presumed to act principally as an agonist at the serotonin 5-HT2A receptor, the shared molecular trigger of the classic psychedelic state, with probable secondary affinity for other serotonin subtypes and monoamine sites reported across the tryptamine class. Direct pharmacological and clinical data are essentially absent, so its potency, duration, and safety margin remain undefined and are inferred only from close structural relatives. It is encountered, if at all, as a rare research chemical rather than an established compound.
- Classic serotonergic tryptamine character (presumed)
- N-alkyl substitution may lengthen duration
- Classic 5-HT2A psychedelic tryptamine
- Unknown potency raises the risk of overshooting
- Anxiety, confusion, raised heart rate and blood pressure
Mechanism
MPT is a ring-unsubstituted tryptamine carrying a methyl and a propyl group on the terminal nitrogen; by analogy to DMT and related tryptamines it is presumed to act as an at the receptor, the receptor that drives the classic psychedelic state, with likely secondary activity at other serotonin (, 5-HT2C) sites. The bulkier N-alkyl groups tend to slow breakdown compared with DMT, which may lengthen its action, but human pharmacokinetic data are essentially absent. Because it is so lightly characterized, any specific affinity figures should be treated as guesses.
receptor fingerprint
receptoragonist (presumed)
receptoragonist (presumed)
Safetyrisks and cautions, not medical advice
As a barely-studied research tryptamine, MPT has no established safe range and its potency is unknown, so misjudging strength is a real hazard. The general tryptamine cautions apply: it can raise heart rate and blood pressure, provoke intense anxiety or confusion, and it is dangerous to combine with MAOIs or other strongly serotonergic drugs because of serotonin toxicity. People with a personal or family history of psychosis should avoid it. Not medical advice.
Subjective profileweighing the evidence above
Almost nothing is known about it, including how strong it is, and unknown potency is precisely how people get hurt with tryptamines. There is no reason to choose this over a psychedelic that has an actual dose-response literature behind it.
Resources
This entry is here for reference.
Research
- 2011first citedClinical toxicology of newer recreational drugs.
- 2018most recentChemistry and Structure-Activity Relationships of Psychedelics
- 1.Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis
- 2.Chemistry and Structure-Activity Relationships of Psychedelics
- 3.Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.
- 4.Clinical toxicology of newer recreational drugs.
4 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
Is MPT well studied?
No. It is an obscure research tryptamine with very little published human data, so its effects and safe range are not established.
How does it work?
By analogy to other psychedelic tryptamines it is presumed to act mainly through 5-HT2A serotonin receptor agonism.
What is the biggest risk?
Its unknown potency and the danger of combining it with MAOIs or other serotonergic drugs, which can cause serotonin toxicity.
Limitations of the evidence
- Almost no human safety data
Adverse effects
- Unknown potency raises the risk of overshooting
- Anxiety, confusion, raised heart rate and blood pressure